Business Description
Mainz Biomed NV
ISIN : NL0015000LC2
Description
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples.
Financial Strength
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.95 | |||||
| Equity-to-Asset | 0.21 | |||||
| Debt-to-Equity | 2.28 | |||||
| Debt-to-EBITDA | -0.3 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -11.18 | |||||
| Beneish M-Score | 70.25 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 9.4 | |||||
| 3-Year EBITDA Growth Rate | -310 | |||||
| 3-Year EPS without NRI Growth Rate | -212.9 | |||||
| 3-Year FCF Growth Rate | -229.6 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 22.61 | |||||
| 9-Day RSI | 26.29 | |||||
| 14-Day RSI | 29.75 | |||||
| 6-1 Month Momentum % | -53.13 | |||||
| 12-1 Month Momentum % | -79.69 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.97 | |||||
| Quick Ratio | 0.91 | |||||
| Cash Ratio | 0.77 | |||||
| Days Inventory | 366.13 | |||||
| Days Sales Outstanding | 39.6 | |||||
| Days Payable | 1717.58 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -21.8 | |||||
| Shareholder Yield % | -76.07 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 56.92 | |||||
| Operating Margin % | -2997.21 | |||||
| Net Margin % | -2934.82 | |||||
| FCF Margin % | -2660.49 | |||||
| ROE % | -368.83 | |||||
| ROA % | -142.29 | |||||
| ROIC % | -245.96 | |||||
| ROC (Joel Greenblatt) % | -840.73 | |||||
| ROCE % | -255.67 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 11.79 | |||||
| PB Ratio | 4.29 | |||||
| EV-to-EBIT | -0.58 | |||||
| EV-to-EBITDA | -0.6 | |||||
| EV-to-Revenue | 16.51 | |||||
| EV-to-Forward-Revenue | 11.38 | |||||
| EV-to-FCF | -0.62 | |||||
| Earnings Yield (Greenblatt) % | -172.41 | |||||
| FCF Yield % | -165.03 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:MYNZ
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Mainz Biomed NV Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.896 | ||
| EPS (TTM) ($) | -1.64 | ||
| Beta | 0 | ||
| Volatility % | 75.04 | ||
| 14-Day RSI | 29.75 | ||
| 14-Day ATR ($) | 0.083357 | ||
| 20-Day SMA ($) | 0.82743 | ||
| 12-1 Month Momentum % | -79.69 | ||
| 52-Week Range ($) | 0.6437 - 6 | ||
| Shares Outstanding (Mil) | 21.89 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Mainz Biomed NV Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Mainz Biomed NV Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Mainz Biomed NV Frequently Asked Questions
What is Mainz Biomed NV(MYNZ)'s stock price today?
The current price of MYNZ is $0.66. The 52 week high of MYNZ is $6.00 and 52 week low is $0.64.
When is next earnings date of Mainz Biomed NV(MYNZ)?
The next earnings date of Mainz Biomed NV(MYNZ) is 2024-05-16 Est..
Does Mainz Biomed NV(MYNZ) pay dividends? If so, how much?
Mainz Biomed NV(MYNZ) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers